Kane Biotech Inc. (CVE:KNE) Director Marc Edwards Acquires 345,000 Shares

Kane Biotech Inc. (CVE:KNE) Director Marc Edwards purchased 345,000 shares of Kane Biotech stock in a transaction dated Tuesday, June 25th. The stock was bought at an average cost of C$0.14 per share, for a total transaction of C$48,300.00.

Kane Biotech Price Performance

Kane Biotech stock opened at C$0.15 on Friday. The company’s 50 day simple moving average is C$0.13 and its 200-day simple moving average is C$0.11. The company has a market capitalization of C$19.88 million, a price-to-earnings ratio of -5.00 and a beta of 0.55. Kane Biotech Inc. has a 1 year low of C$0.05 and a 1 year high of C$0.17. The company has a debt-to-equity ratio of 1,164.24, a quick ratio of 0.39 and a current ratio of 0.31.

Kane Biotech (CVE:KNE) last announced its earnings results on Thursday, May 23rd. The company reported C($0.01) earnings per share for the quarter. The company had revenue of C$0.05 million for the quarter.

About Kane Biotech

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.